1. Home
  2. HYPD vs BAFN Comparison

HYPD vs BAFN Comparison

Compare HYPD & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HYPD
  • BAFN
  • Stock Information
  • Founded
  • HYPD 2014
  • BAFN 1999
  • Country
  • HYPD United States
  • BAFN United States
  • Employees
  • HYPD N/A
  • BAFN N/A
  • Industry
  • HYPD
  • BAFN Savings Institutions
  • Sector
  • HYPD
  • BAFN Finance
  • Exchange
  • HYPD NYSE
  • BAFN Nasdaq
  • Market Cap
  • HYPD 73.3M
  • BAFN 63.2M
  • IPO Year
  • HYPD 2018
  • BAFN N/A
  • Fundamental
  • Price
  • HYPD $8.26
  • BAFN $12.69
  • Analyst Decision
  • HYPD
  • BAFN
  • Analyst Count
  • HYPD 0
  • BAFN 0
  • Target Price
  • HYPD N/A
  • BAFN N/A
  • AVG Volume (30 Days)
  • HYPD 969.8K
  • BAFN 15.4K
  • Earning Date
  • HYPD 08-11-2025
  • BAFN 07-29-2025
  • Dividend Yield
  • HYPD N/A
  • BAFN 2.54%
  • EPS Growth
  • HYPD N/A
  • BAFN 102.38
  • EPS
  • HYPD N/A
  • BAFN 1.90
  • Revenue
  • HYPD $67,063.00
  • BAFN $78,211,000.00
  • Revenue This Year
  • HYPD $7,680.45
  • BAFN N/A
  • Revenue Next Year
  • HYPD $315.38
  • BAFN N/A
  • P/E Ratio
  • HYPD N/A
  • BAFN $7.20
  • Revenue Growth
  • HYPD 663.82
  • BAFN 0.67
  • 52 Week Low
  • HYPD $0.85
  • BAFN $11.98
  • 52 Week High
  • HYPD $112.80
  • BAFN $19.75
  • Technical
  • Relative Strength Index (RSI)
  • HYPD N/A
  • BAFN 33.66
  • Support Level
  • HYPD N/A
  • BAFN $14.50
  • Resistance Level
  • HYPD N/A
  • BAFN $15.28
  • Average True Range (ATR)
  • HYPD 0.00
  • BAFN 0.44
  • MACD
  • HYPD 0.00
  • BAFN -0.13
  • Stochastic Oscillator
  • HYPD 0.00
  • BAFN 3.72

About HYPD HYPERION DEFI INC

Hyperion DeFi Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: